What Bicara Therapeutics (BCAX) Said on Its Q3 Earnings Call

Bicara (BCAX) Q3 2026 Earnings Call Transcript

Management outlines interim analysis timing and new survival data plans.

Bicara plans mid-2027 interim analysis as $442.3M cash runway extends into first half of 2029 (NASDAQ:BCAX)

Bicara Q3 2026: FORTIFI-HN01 hits key enrollment milestone, interim OS analysis planned, with cash runway into 2029.

What Bicara Therapeutics (BCAX) Said on Its Q3 Earnings Call

Bicara Therapeutics (NASDAQ:BCAX) said its pivotal study of FICERA in a form of advanced head and neck cancer has reached sufficient enrollment to support a planned top-line interim analysis in mid-2027. The company also confirmed plans for an interim overall survival analysis in the FORTIFI-HN01 t

What Abeona Therapeutics (ABEO) Said on Its Q3 Earnings Call

Abeona Therapeutics (NASDAQ:ABEO) reported higher ZEVASKYN revenue for the third quarter of 2026 and announced the acquisition of a late-stage drug candidate for eosinophilic esophagitis, as it seeks to expand beyond its first commercial product. Net revenue from ZEVASKYN, the company’s treatment for recessive dystrophic epidermolysis bullosa, or RDEB, rose 18% from the previous quarter […]